Research Division for Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Insitute (KAERI), 29 Geumgu-gil, Jeongeup-si, Jeollabuk-do, Republic of Korea.
Daegu-Gyeongbuk Medical Innovation Foundation, Medical Device Development Center, Daegu, Republic of Korea.
PLoS One. 2018 Apr 4;13(4):e0194341. doi: 10.1371/journal.pone.0194341. eCollection 2018.
Dexamethasone (Dex) is widely used in the management of leukemia and lymphoma. While Dex is commonly used for hematological malignancies, the effects of Dex in solid cancer cells remain controversial. To develop a more effective anticancer drug for solid cancers, Dex was modified by ionizing radiation and the anticancer activity of ionizing-radiation-irradiated Dex (Dex-IR) was investigated in human lung cancer cells. Using the MTT assay, the proliferation of non-small cell lung cancer cells was significantly inhibited after treatment with Dex-IR compared with Dex. Furthermore, Dex-IR induced apoptotic cell death and cell cycle arrest of H1650 human lung cancer cells. The invasiveness of H1650 cells was significantly reduced and the matrix metalloproteinase activity was strongly suppressed. These results indicate that Dex-IR acts as a tumor suppressor by both inducing apoptosis and arresting the cell cycle. Although the structure of Dex-IR remains to be determined, our results suggest it may be useful as a novel anticancer agent for the treatment of solid cancers.
地塞米松（Dex）广泛用于白血病和淋巴瘤的治疗。虽然 Dex 常用于血液系统恶性肿瘤，但 Dex 在实体癌细胞中的作用仍存在争议。为了开发更有效的实体癌抗癌药物，我们通过离子辐射对 Dex 进行了修饰，并研究了电离辐射照射的 Dex（Dex-IR）在人肺癌细胞中的抗癌活性。使用 MTT 测定法，与 Dex 相比，Dex-IR 处理后非小细胞肺癌细胞的增殖明显受到抑制。此外，Dex-IR 诱导 H1650 人肺癌细胞的凋亡性细胞死亡和细胞周期停滞。H1650 细胞的侵袭性明显降低，基质金属蛋白酶活性也受到强烈抑制。这些结果表明 Dex-IR 通过诱导细胞凋亡和阻止细胞周期发挥肿瘤抑制作用。尽管 Dex-IR 的结构仍有待确定，但我们的结果表明，它可能是治疗实体癌的新型抗癌药物。
